Latest news with #NCI
Yahoo
8 hours ago
- Business
- Yahoo
CBA closes stake sale in Bank of Hangzhou to NCI
Commonwealth Bank of Australia (CBA) has concluded the sale of its remaining shareholding in Bank of Hangzhou (HZB) to New China Life Insurance (NCI), a Beijing-based life insurer. The transaction marks the completion of CBA's divestment from the Chinese bank. In January this year, CBA signed an agreement to sell its remaining 5.45% stake in HZB to NCI, which is said to yield approximately A$940m (then $593m) in gross proceeds for CBA. Established in September 1996, HZB is located in Zhejiang province, China. It is listed on the Shanghai Stock Exchange. NCI is listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange. CBA expects the transaction to boost its Common Equity Tier 1 ratio by around 17 basis points. Meanwhile, recently, CBA was in the news for migrating its data platform to Amazon Web Services (AWS) to improve integration with other banking channels. This transition aims to deliver personalised experiences for customers and employees using data, AI, and analytics technologies. The bank has been making several moves in recent times to support its AI push. In March, CBA launched the Seattle Tech Hub in the US to improve its AI capabilities and customer service. The Hub is said to serve as a 'strategic gateway' for CommBank's technology teams. The same month, the bank announced an expanded partnership and investment in AI research company Anthropic, aiming to improve its in-house technology capabilities and support focus on key AI use cases. "CBA closes stake sale in Bank of Hangzhou to NCI" was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-06-2025
- Business
- Yahoo
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – James NEW YORK, June 3, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris has entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center. This agreement follows the successful completion of a pilot program which enrolled patients across several OSUCCC – James cancer care service lines on the Veris Cancer Care Platform™. Pursuant to the agreement Veris and OSUCCC – James entered into a long-term, multi-project strategic partnership to utilize, and further the development and commercialization of the Veris Cancer Care Platform and its implantable physiologic monitor. The agreement includes expansion of commercial utilization of the platform across cancer care service lines; full electronic health record (EHR) integration; initiation of a large clinical registry of patients enrolled on the platform to be launched in the coming weeks; and launch of a large clinical trial of patients receiving the implantable physiologic monitor, to be launched upon FDA clearance, expected next year. It also calls for close collaboration on the development of clinical cancer care pathways, platform software enhancements, and best practices for clinical use of the implantable physiological monitor. "We are thrilled to advance our strategic partnership with OSUCCC – James, one of the largest and most prestigious academic cancer centers in the nation, following the successful completion of a pilot program demonstrating the strong clinical utility of our platform," said Brian deGuzman, M.D., Chief Operating Officer of Veris Health. "This commercial transition represents a major milestone for Veris. We look forward to working closely with the OSUCCC – James team to enhance the care of thousands of cancer patients there every year." "At the OSUCCC – James, delivering personalized, world-class cancer care remains our top priority," said David Cohn, M.D., M.B.A., Chief Operating Officer and Chair of Gynecologic Oncology at The James Cancer Hospital and Solove Research Institute. "After a successful pilot program, we are excited to be entering into a long-term strategic partnership with Veris Health to expand access to the Veris Cancer Care Platform and enhance the care of our patients." The Veris Cancer Care Platform is a comprehensive digital cancer care platform with remote physiological data collection, symptom reporting, telehealth capability, and electronic health record integration. The platform seeks to offer enhanced personalized cancer care through the early detection of complications, reduced unplanned hospitalizations, the provision of longitudinal trends of physiological and clinical data, data-driven risk management tools, and increased patient and provider satisfaction. Cancer patients enrolled on the platform receive a VerisBox™ of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via embedded cellular connections. A complementary patient portal enables patients to report symptoms, as well as general health and quality of life parameters, to their cancer care team through the Veris patient smartphone app. The app also allows patients to invite caretakers and family members to follow along on their cancer care journey. Veris is also developing an implantable physiological monitor, designed to be implanted alongside a vascular access port, which will interface with the Veris Cancer Care Platform. The implantable monitor will further enhance the clinical and commercial value of the platform by providing remote physiologic data independent of patient compliance. Cancer centers and oncology practices interested in learning more about Veris and the Veris Platform, please visit to contact a company representative. About PAVmed and Veris PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Veris Health Inc., is a digital health company whose lead product is a digital cancer care platform with physiologic data collection, symptom reporting and telehealth functions, designed to improve personalized cancer care through remote patient monitoring. Veris has also been developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris cancer care platform. Its other majority-owned subsidiary, Lucid Diagnostics, is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. For more and for more information about PAVmed, please visit For more information about Veris Health, please visit For more information about Lucid Diagnostics, please visit About The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (the "OSUCCC – James"), is the only cancer program in the United States that features a National Cancer Institute (NCI)-designated comprehensive cancer center aligned with a nationally ranked academic health center and a freestanding cancer hospital on the campus of one of the nation's largest public universities. The OSUCCC – James has been designated as an NCI Comprehensive Cancer Center since 1976. Also, it is one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer agents provided by the NCI. As the cancer program's adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report for 25 years and has achieved Magnet® recognition, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors, more than 1.1 million square feet and 356 inpatient beds, The James is the third-largest cancer hospital in the nation. The OSUCCC – James is a global leader in such emerging disciplines as cellular therapy and immuno-oncology. In 2017, the OSUCCC – James was among the first hospitals in the United States to offer the first cellular therapy for blood cancers, known as CAR T-cell therapy, and is playing a major role in the continuing development of this and other cellular therapies. To learn more about cancer treatment and clinical trials at the OSUCCC – James, visit Forward-Looking Statements This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. View original content to download multimedia: SOURCE PAVmed Inc. Sign in to access your portfolio
Yahoo
01-06-2025
- Business
- Yahoo
A funding flashpoint, Pfizer's $1B poster and AstraZeneca advertising
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Funding cancer research isn't usually a political flashpoint. But as the Trump administration signals its desire to drastically cut the budget of the National Cancer Institute, the American Society of Clinical Oncology is finding itself forced to defend what is usually a bipartisan policy. "If implemented, these cuts would be devastating to the pace and progress of cancer research in America," ASCO CEO Clifford Hudis said in a Friday statement. 'ASCO maintains that federally funded cancer research is the single best investment our country has ever made." ASCO's annual meeting this year provides a convincing example. A large study funded by the NCI found that adding the immunotherapy Tecentriq to a common chemotherapy regimen can halve the risk of disease recurrence or death in patients with a certain form of colon cancer. These data, said one of the researchers involved, will change clinical practice. But they may not have been as easily obtained without the help of the NCI, said Joel Saltzman, vice chair of regional oncology at the Cleveland Clinic's Taussig Cancer Center, in a press conference held for reporters. 'This was a study that took five years to accrue patients to. It was open at 300 sites,' he said. 'A study like this would just not have been feasible without the federal funding from the National Cancer Institute.' — Ned Pagliarulo On Saturday, doctors and biotechnology executives got a closer look at Pfizer's latest billion-dollar acquisition, a bispecific antibody from China's 3SBio, code-named SSGJ-707, that blocks the proteins PD-1 and VEGF. 3SBio, which licensed Pfizer's rights to SSGJ-707 for $1.25 billion upfront, presented mid-stage study data in a poster session that hinted at the drug's promise in non-small cell lung cancer. The Phase 2 study involved previously untreated people whose tumors express the protein PD-L1. Treatment shrank tumors in about two-thirds of participants given a dose of 10 milligrams infused every three weeks, with lower response rates at doses of 5, 20 and 30 milligrams. Nearly all patients experienced side effects, notably liver enzyme elevations and increased cholesterol. More than half on the 20 and 30 milligram doses had side effects judged to be 'severe or medically significant,' while on lower doses only about 1 in 4 did. Researchers, led by Lin Wu of Hunan Cancer Hospital in China, wrote that the data 'support further evaluation' of the 10 milligram dose. Four trials are listed as underway at with a fifth planned. The 3SBio data came a day after Summit Pharmaceuticals and Akeso released Phase 3 data from their PD-1/VEGF combination treatment, now one of the most closely watched drugs in all of oncology. — Jonathan Gardner Walk around Chicago this weekend and you're likely to see an ad for AstraZeneca's cancer research, often emblazoned on the sides of bus stops. Take an Uber to McCormick Place, the convention center that houses ASCO for five days, and you might be reminded by an ad on the app that it's been 10 years since the initial approval of Tagrisso, which now ranks among the top 20 most lucrative pharmaceutical products by sales. All pharma companies advertise at ASCO, of course, but AstraZeneca has a lot of talk about this year. For the seventh year in a row, the maker of Tagrisso, Imfinzi and Enhertu has trial data highlighted in the ASCO plenary session — an occasion AstraZeneca executives are marking with a pin that weaves the number '7' between the 'A' and 'Z' of their company's logo. Data from one such highlighted study indicate that an AstraZeneca drug called camizestrant could be swapped in for so-called aromatase inhibitors as part of an initial treatment regimen for the most common form of advanced breast cancer. Aromatase inhibitors, one AstraZeneca bus stop ad reminds possibly confused Chicagoans, were state of the art in the 1990s. 'Then again, so were videotapes,' it adds. Camizestrant is not yet approved, but AstraZeneca expects it will eventually become a major product. Its importance is reflected in its name: the 'cami' root is a nod to the British drugmaker's Cambridge laboratories, where camizestrant originated. — Ned Pagliarulo Haydar Frangoul, a pediatric hematologist and oncologist, is used to presenting at medical meetings. But ASCO isn't the usual forum for Frangoul, who played a major role in testing the CRISPR gene editing treatment Casgevy for sickle cell disease. 'I was shocked they wanted to hear about sickle cell at ASCO,' Frangoul said Saturday, opening a joint session on gene therapy held by ASCO and the American Association of Cancer Research. Frangoul walked the assembled cancer doctors and researchers through the study that supported Casgevy's U.S. approval in December 2023. Jimi Olaghere, a patient in that study, described his life before treatment, and how Casgevy has changed it. Their reflections spotlighted what gene therapy can accomplish, even as the field falters amid waning investor interest, dried-up funding and persistent safety concerns. It's an important reminder even in oncology, which is perhaps not as often associated with gene therapy as rare diseases like sickle cell. Kymriah, a CAR-T cell treatment for leukemia, was the first therapy based on gene transfer technology to be cleared by the FDA. Five other CAR-Ts have been approved since, as have several other T cell-based medicines. More are likely coming, too. The session closed with a presentation from Katy Revzani, head of the MD Anderson Cancer Center's cell therapy institute, about her hospital's research exploring NK cell therapy, which she said could be safer and easier to produce off of the shelf. — Ned Pagliarulo Recommended Reading Pfizer buys into PD-1/VEGF competition with 3SBio deal
Politico
29-05-2025
- Health
- Politico
Cancer doc's $50B ask to Trump
INFLUENCERS Dr. Wafik El-Deiry, a cancer researcher and associate dean for oncology at Brown University, has an unlikely sales pitch for President Donald Trump: Pick me to lead the nation's cancer research and give me a lot more money to spend on it. Despite slashing billions in health research grants and proposing further cuts in next year's budget, Trump is considering El-Deiry to lead the National Cancer Institute after a recent interview for the job. 'It has been clear to me for some time that the budget of NCI should be somewhere between $25 billion and $50 billion,' El-Deiry wrote in The Cancer Letter, an industry publication, in May. He argued that the U.S. has underinvested in cancer research for decades — even amid former President Joe Biden's cancer moonshot plan to halve the death rate from the disease — and is losing ground to foreign rivals. 'It is important to recognize that a current very big elephant is that even if the 40 percent reduction in NIH budget is somehow avoided, the lack of investment for two decades put the U.S. behind,' he added. With NCI's $7.2 billion budget partly frozen by Trump due to his ideological disputes and feuds with universities, it's a bold pitch. The position has been vacant since the last institute head, W. Kimryn Rathmell, quit three days before Trump's inauguration. But El-Deiry has something in common with many others serving in top jobs in Trump's health department: He was attacked online for his views during the pandemic. NIH head Jay Bhattacharya, the Stanford health policy professor and critic of lockdowns, would be his boss if Trump chooses El-Deiry to lead the institute. They met online during the pandemic when Bhattacharya, who has made free speech and scientific dissent central to his NIH agenda, came under heavy criticism for arguing that most Americans should go about their daily lives. El-Deiry spoke with Erin about where his views dovetail with the administration's and where they diverge. This interview has been edited for length and clarity. Can science and Make America Healthy Again coexist? I actually think Trump's boldness and disruptiveness could work in the favor of science. But there has to be more discourse about the future. I don't think an America First agenda will succeed in science if we don't invest in research and science to be No. 1. One tenet of the MAHA agenda is that Americans spend more on health care but have shorter life expectancy and worse health outcomes than countries that spend less. I call it atrophy, neglect and abandonment over the last 20 years in investing in science. Maybe that neglect and lack of investment for decades is in part responsible for current life expectancy. How do you square that with DOGE's push to streamline government? I'm not suggesting taxpayer money allocated for research is a handout or an entitlement. I absolutely believe there should be accountability, and there shouldn't be waste, there shouldn't be inefficiency. God knows, there's plenty of that, and maybe some corruption on top of that. All of those things need to be addressed. I would look at it a little bit differently. We've invested more. We've led the world. There isn't a better system. We've solved many of the world's health problems. We've made breakthroughs. Most of the Nobel Prizes going back decades are based on NIH research and discoveries at our academic institutions. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. There's a new vaping product — but it's not a vape. Tobacco company Philip Morris International says its IQOS device is healthier than cigarettes and is planning a relaunch in the U.S., according to Stat. However researchers are worried that IQOS, which uses tobacco, is more harmful than e-cigarettes, which don't. Share any thoughts, news, tips and feedback with Danny Nguyen at dnguyen@ Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: Dannyn516.70, CarmenP.82, RuthReader.02 or ErinSchumaker.01. SAFETY CHECK The Coalition for Health AI has announced its first assurance lab for vetting health care AI. The alliance of health systems, clinics, and tech companies has been working for years to launch labs to help AI makers prove their products are safe to use in medicine. This week, BeeKeeperAI became the first CHAI-certified assurance lab. The company tests algorithms on health system data while keeping patient information confidential. The CHAI certification qualifies it to rapidly test AI models on real-world chronic health failure datasets from Morehouse School of Medicine in Atlanta and New York's Icahn School of Medicine at Mount Sinai. To start, BeeKeeper will only vet heart failure-related AI. Why it matters: Rolling out the labs is taking longer than CHAI initially expected and the project's impact on the market remains unclear. Last summer, CHAI said that some 30 institutions were interested in becoming assurance labs. By December, the organization said it was certifying labs within Mayo Clinic, UMass Memorial Medical Center, and five startups. It initially planned to have its first labs certified in the first quarter of this year. BeeKeeperAI CEO Michael Blum says assurance labs like his will add more disease categories over time. For now the scope is narrowly on heart health. 'You'll pick the big, important disease spaces where people are developing drugs or developing algorithms, because they want to impact big disease problems,' he said. He pointed to an opportunity to vet neurodegenerative disease-related AI and cancer models. But to do so, BeeKeeper needs health system partners who can provide specialized datasets that the AI can be vetted against. What's next: The debate over how best to vet AI's use in health continues. Solera Network, which connects patients with digital health benefits — like at-home blood pressure readings and online physical therapy — is planning to announce a framework for governing AI products on its platform next week. The Digital Medicine Society, which partners with drug and biotech companies to promote health tech, is working on AI certification programs. So is which seeks to bring doctors and AI companies together to improve the tech tools, and the National Committee for Quality Assurance, a Washington nonprofit that offers health organizations a seal of approval. The Peterson Health Technology Institute is also working on a way to evaluate these tools. CHAI isn't putting all its money on the assurance lab concept. Earlier this year, CHAI launched a national AI registry that will collect AI model cards, which contain information about how a given algorithm is trained and performs. Avanade, a joint venture between Microsoft and Accenture, is powering that registry with its Safe AI Governance Engine, which plans to one day vet individual health systems' AI. SMALL BYTES Despite persistent legal challenges and lobbying opposition, states are moving ahead with legislation to protect kids from online health harms. This week, Texas' Republican governor, Greg Abbott, signed a bill that will make Apple and Google's app stores responsible for ensuring kids get parental consent before downloading apps on their phones. The state legislature also passed a bill banning minors from creating social media accounts, though Abbott has yet to sign it. Meanwhile, Nebraska's legislature has passed the Age-Appropriate Online Design Code Act, which would require social media companies to offer young users more tools to keep them safe on their platforms and limit the amount of data they can collect. It's among several states, including California and Maryland, to pass this type of legislation. Social media state laws have faced significant legal challenges from NetChoice, a large tech industry lobbying group. And yet, states seem determined to pass laws that address mental health issues associated with these platforms.
Time of India
26-05-2025
- Health
- Time of India
Central location a huge advantage; Nagpur can be major research hub: Amit Shah
1 2 Nagpur: Union home minister Amit Shah on Monday emphasised the strategic importance of Nagpur in India's healthcare landscape and called for strengthening research activities at the National Cancer Institute (NCI). "Nagpur is centrally located and receives patients from across the country. Any health research conducted here will benefit the entire nation," Shah said while performing the bhoomipujan of 'Swasti Bhavan' — a new residential facility for caregivers of cancer patients at NCI. Praising the efforts of the NCI management and its promoters, Shah said, "I have visited many institutions, but after seeing NCI, I can confidently say that it will soon be counted among the best cancer institutes in the country." He assured full support in developing state-of-the-art research infrastructure at the institute. Swasti Bhavan has been supported under the corporate social responsibility (CSR) initiative of Pernod Ricard India, with architectural designs by JJ Consultants. The facility aims to provide affordable housing, nutrition, and holistic care to families of cancer patients undergoing long-term treatment at NCI. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trade Bitcoin & Ethereum – No Wallet Needed! IC Markets Start Now Undo Shah was joined by chief minister Devendra Fadnavis, state revenue minister Chandrashekhar Bawankule, NCI president Sunil Manohar, vice-president Ajay Sancheti, CEO Shailesh Joglekar, treasurer Anand Aurangabadkar and NCI medical director Dr Anand Pathak. Hingna MLA Sameer Meghe and senior officials from Pernod Ricard India including CEO Jean Touboul and National Head of Corporate Affairs Prasanna Mohile were also present. Fadnavis, speaking on the occasion, said the idea of the facility originated when he saw relatives sleeping in the open at the NCI premises. "It moved me deeply, and we immediately began planning for a dedicated residential complex. Today's bhoomipujan is a step toward that vision," he said. He also assured Shah that the state govt and NCI would work to transform the institution into a major research hub. Shah lauded Joglekar and Fadnavis, stating that both leaders turned personal loss into public service by supporting cancer care initiatives. "Unlike in the West, where families often remain away, in India, the entire family is emotionally involved in the patient's journey. Swasti Bhavan is a novel concept that respects this social fabric," he added. Shah also underlined the Modi govt's commitment to affordable healthcare, citing the Ayushman Bharat scheme that provides free treatment up to Rs5 lakh for over 60 crore citizens. BOX Swasti Niwas: Stay with your loved one Dedicated residential facility for cancer patients and caregivers within NCI Will accommodate around 400 patients and their families Supported by Pernod Ricard India's CSR initiative Will cater to paediatric cancer patients and their families requiring prolonged stays 1.7 lakh sq ft centre will include convenience centre, food court
